Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY: Dostarlimab +/- Niraparib in Advanced Endometrial Cancer
NCT03981796Phase 3Active, not recruiting
- Start
- Jul 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab and niraparib in endometrial cancer (EC) (4 arms). Primary endpoints: Progression-Free Survival (Investigator Assessment) up to 6 years and Overall Survival up to 6 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
dostarlimabniraparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03981796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03981796.